Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization

Cancer Genetics and Cytogenetics

Volumn 182, Issue 2, 2008, Pages 116-121

  Rákosy, Zsuzsa ^a,b   Vízkeleti, Laura ^a   Ecsedi, Szilvia ^a   Bégány, Ágnes ^a   Emri, Gabriella ^a   Ádány, Róza ^a,b   Balázs, Margit ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P14;

ADULT; ARTICLE; BLADDER CANCER; CENTROMERE; CHROMOSOME 9P; CONTROLLED STUDY; COPY NUMBER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE NUMBER; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL;

ADULT; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

ALIAS;

EID: 41749114987     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.01.008     Document Type: Article

References (22)

1. Poetsch M., Dittberner T., and Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 13 (2003) 29-33
2. Herlyn M., Ferrone S., Ronai Z., Finerty J., Pelroy R., and Mohla S. Melanoma biology and progression. Cancer Res 61 (2001) 4642-4643
3. Slominski A., Wortsman J., Carlson A.J., Matsuoka L.Y., Balch C.M., and Mihm M.C. Malignant melanoma. Arch Pathol Lab Med 125 (2001) 1295-1306
4. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N.A., Ding W., Hussey C., Tran T., Miki Y., Weaver-Feldhaus J., McClure M., Aitken J.F., Anderson D.E., Bergman W., Frants R., Goldgar D.E., Green A., MacLennan R., Martin N.G., Meyer L.J., Youl P., Zone J.J., Skolnick M.H., and Cannon-Albright L.A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 23-26
5. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
6. Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., and Hayward N.K. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57 (1997) 4868-4875
7. Casorzo L., Luzzi C., Nardacchione A., Picciotto F., Pisacane A., and Risio M. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res 15 (2005) 155-160
8. Balázs M., Adám Z., Treszl A., Bégány A., Hunyadi J., and Adány R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46 (2001) 222-232
9. Bastian B.C., Olshen A.B., LeBoit P.E., and Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163 (2003) 1765-1770
10. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Bröcker E.B., LeBoit P.E., Pinkel D., and Bastian B.C. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
11. Koynova D., Jordanova E., Kukutsch N., van der Velden P., Toncheva D., and Gruis N. Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. J Cancer Res Clin Oncol 133 (2007) 117-123
12. Rousseau Jr. D.L., and Gershenwald J.E. The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol 31 (2004) 415-425
13. Perry A., Banerjee R., Lohse C.M., Kleinschmidt-DeMasters B.K., and Scheithauer B.W. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12 (2002) 183-190
14. Maitra A., Kern S.E., and Hruban R.H. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 20 (2006) 211-226
15. Ushio Y., Tada K., Shiraishi S., Kamiryo T., Shinojima N., Kochi M., and Saya H. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci 8 (2003) e281-e288
16. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119 (2006) 1513-1518
17. INK4a/CD3 alternate staining. Cytometry A 71 (2007) 327-333
18. Gruis N.A., and Bergman W. From gene to disease; from p16 to melanoma. [In Dutch]. Ned Tijdschr Geneeskd 144 (2000) 2100-2102
19. INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 138 (1998) 13-21
20. INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18 (1999) 2527-2532
21. Tran T.P., Titus-Ernstoff L., Perry A.E., Ernstoff M.S., and Newsham I.F. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control 13 (2002) 675-682
22. Reed J.A., Loganzo Jr. F., Shea C.R., Walker G.J., Flores J.F., Glendening J.M., Bogdany J.K., Shiel M.J., Haluska F.G., Fountain J.W., and Albino A.P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55 (1995) 2713-2718